UCB shares rise over 5% after first-half beat on Bimzelx; guidance raised

Published 31/07/2025, 12:10
© Reuters.

Investing.com -- Shares of UCB (EBR:UCB) rose more than 5% on Thursday after the drugmaker reported better-than-expected first-half results, lifted by strong U.S. sales of Bimzelx, and raised its 2025 guidance.

Revenue for the six months ended June 30 rose 25% year-over-year to €3.49 billion, exceeding the Visible Alpha consensus of €3.22 billion by 8%. 

Net sales totaled €3.32 billion, up from €2.64 billion in the year-ago period. Adjusted EBITDA rose 58% to €1.03 billion, 11% ahead of consensus, with a margin of 29.6%. Core earnings per share were €3.53, in line with estimates.

The beat was driven by Bimzelx, which posted global sales of €799 million, compared with €215 million a year earlier. U.S. sales came in at €545 million, 53% above expectations. 

Psoriasis accounted for 61% of total Bimzelx sales. The company did not disclose the paid-to-bridge ratio but noted higher levels of paid prescriptions.

Cimzia brought in €959 million in revenue, up from €936 million and 2% above consensus. 

Among neurology drugs, Briviact generated €377 million, a 2% beat, while Keppra and Vimpat recorded €309 million and €172 million, respectively. 

Fintepla and Rystiggo missed expectations, while Zilbrysq exceeded forecasts with €93 million in sales, 26% above consensus.

Total (EPA:TTEF) operating costs rose, with selling, general and administrative expenses climbing 20% to €1.28 billion, largely due to direct-to-consumer advertising for Bimzelx and investments in newer products. 

Research and development spending increased to €860 million from €789 million. Adjusted EBIT stood at €720 million, 11% above consensus.

Following the first-half results, UCB raised its full-year revenue forecast to above €7 billion from €6.7 billion. 

The new outlook remains slightly above the €6.73 billion consensus. The company now expects an adjusted EBITDA margin of 30% and core EPS above €7.25, compared with analyst expectations of €7.12.

Jefferies analysts described the updated guidance as cautious relative to the strong first-half performance, citing competitive uncertainties and recent commentary from Novartis (SIX:NOVN) about the hidradenitis suppurativa market.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.